Table 1.
Patient characteristics
| Characteristic | N = 45 |
|---|---|
|
| |
| Age, median (range) | 31 (20–60) |
|
| |
| Male, n (%) | 16 (36%) |
|
| |
| Stage at Diagnosis, n (%) | |
| I | 3 (7%) |
| II | 24 (53%) |
| III | 6 (13%) |
| IV | 12 (27%) |
|
| |
| Stage at Enrollment, n (%) | |
| I | 6 (13%) |
| II | 22 (49%) |
| III | 6 (13%) |
| IV | 11 (24%) |
|
| |
| Primary therapy received, n (%) | |
| ABVD/AVD | 43 (96%) |
| ABVE-PC | 1 (2%) |
| Stanford V | 1 (2%) |
|
| |
| Prior consolidative radiotherapy, n (%) | 8 (18%) |
|
| |
| Baseline disease characteristics, n (%) | |
| B symptoms at diagnosis | 18 (40%) |
| Extranodal disease at diagnosis | 12 (27%) |
| Spleen involved at diagnosis | 7 (16%) |
|
| |
| Response to frontline therapy, n (%) | |
| Primary Refractory* | 29 (64%) |
| Relapse 3–12 months after treatment completion | 8 (18%) |
| Relapse > 12 months after treatment completions | 8 (18%) |
|
| |
| Relapse disease characteristics, n (%) | |
| B symptoms at relapse | 1 (2%) |
| Extranodal involvement at relapse | 11 (24%) |
| Spleen involvement at relapse | 4 (9%) |
*
For patients with progression within 3 months, best response (including interim PET) to frontline therapy for patients with primary refractory disease includes: PD (1 patient), PR (14 patients), and CR (14 patients)
ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine
AVD: Doxorubicin, vinblastine, dacarbazine
ABVD/AVD: No patient received AVD alone. However, this group includes patients who received ABVD alone as well as those who initiated ABVD and subsequently omitted bleomycin and finished their primary treatment with AVD
ABVE-PC: doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide